v3.26.1
Revenue (Tables)
6 Months Ended
Jun. 30, 2026
Revenue [abstract]  
Schedule of Revenue Recognized in Unaudited Condensed Consolidated Interim Statements of Profit or Loss

Revenue has been recognized in the unaudited condensed consolidated interim statements of profit or loss with the following amounts:

 

Three Months Ended
June 30,

 

 

Six Months Ended
June 30,

 

(EUR’000)

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Revenue

 

 

 

 

 

 

 

 

 

 

 

 

Commercial products

 

 

314,910

 

 

 

153,663

 

 

 

555,763

 

 

 

249,690

 

Services and clinical supply

 

 

4,856

 

 

 

3,570

 

 

 

9,965

 

 

 

7,094

 

Licenses

 

 

2,473

 

 

 

812

 

 

 

3,112

 

 

 

2,214

 

Milestones

 

 

17,046

 

 

 

 

 

 

17,046

 

 

 

 

Total revenue

 

 

339,285

 

 

 

158,045

 

 

 

585,886

 

 

 

258,998

 

Specified per geographical area

 

 

 

 

 

 

 

 

 

 

 

 

United States (1)

 

 

265,471

 

 

 

108,344

 

 

 

474,548

 

 

 

181,976

 

Europe (2)

 

 

49,671

 

 

 

27,894

 

 

 

85,989

 

 

 

49,222

 

Rest of World (1)

 

 

24,143

 

 

 

21,807

 

 

 

25,349

 

 

 

27,800

 

Total revenue

 

 

339,285

 

 

 

158,045

 

 

 

585,886

 

 

 

258,998

 

(1)
Beginning with the year ended December 31, 2025, revenue related to the United States has been disclosed separately. Comparatives for the United States and Rest of World have been restated for comparative purposes.
For the three and six months ended June 30, 2026, Denmark, the country of domicile, contributed €3.6 million and €8.1 million, respectively, of revenue.
Schedule of Revenue From Sale of Commercial Products

Revenue from sale of commercial products was as follows:

 

Three Months Ended
June 30,

 

 

Six Months Ended
June 30,

 

(EUR’000)

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Revenue from commercial products

 

 

 

 

 

 

 

 

 

 

 

 

YORVIPATH®

 

 

252,114

 

 

 

102,957

 

 

 

449,010

 

 

 

147,646

 

SKYTROFA®

 

 

55,214

 

 

 

50,706

 

 

 

99,171

 

 

 

102,044

 

YUVIWEL®

 

 

7,582

 

 

 

 

 

 

7,582

 

 

 

 

Total revenue from commercial products

 

 

314,910

 

 

 

153,663

 

 

 

555,763

 

 

 

249,690